Home > Neurology > AAN 2022 > Multiple Sclerosis > Evobrutinib reduces volume of slowly expanding lesions

Evobrutinib reduces volume of slowly expanding lesions

Presented By
Prof. Douglas Arnold, McGill University, Canada
Conference
AAN 2022
Doi
https://doi.org/10.55788/77e06c67
The highly selective Bruton’s tyrosine kinase (BTK) inhibitor evobrutinib reduced the volume of slowly expanding lesions (SEL) in a phase 2 trial. This effect was dose-dependent and especially apparent in more advanced multiple sclerosis (MS). This is the first evidence that a BTK inhibitor impacts brain lesions associated with chronic inflammation and tissue loss. Evobrutinib is a highly selective BTK inhibitor that targets B cells, macrophages, and microglia. In a phase 2 trial (NCT02975349) in patients with relapsing MS, 75 mg twice-daily evobrutinib reduced T1 gadolinium-enhancing lesions versus placebo during weeks 12 through 24 [1]. The current study focused on the effect of evobrutinib versus a comparator on an emerging MRI biomarker: SELs, also referred to as “smouldering lesions” [2]. SELs are chronically active, demyelinated MS lesions, l...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on